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T he observation that Ro/SS-A (Ro) autoantibodies are frequently found in mothers and their infants with neonatal lupus erythematosus (NLE) suggested that these autoantibodies might playa role in the patho-genesis of the cardiac and skin injuries that occur in 
NLE. This hypothesis was strengthened by observations that the 
majority of patients with subacute cutaneous lupus erythematosus 
(SCLE) have Ro autoantibodies and that NLE and SCLE skin lesions 
are clinically and histopathologically similar. Furthermore, Lee and 
co-workers demonstrated that intravenously administered Ro auto-
antibodies were selectively deposited in and about the basal kerati-
nocytes of human skin grafted on immunodeficient mice [1]. This 
immune deposition was augmented dramatically when the graft 
was pre-irradiated with ultraviolet B light, a known provocative 
agent of SCLE. Additionally the pattern of immune deposition 
closely mimicked the pattern found in NLE and SCLE skin lesions 
and paralleled the level of skin injury seen histopathologically in 
these two disorders. 
Over the past several years it has been learned that there are 
several different proteins that react with Ro autoantibody contain-
ing autoimmune sera. Three dissimilar human genes that encode Ro 
autoantibody-reactive proteins with molecular weights of 46, 52, 
and 60-kilodaltons (kD) have been characterized [2]. The 52- and 
60-kD proteins, whose functions remain unknown, are reactive 
with the majority of sera that contain Ro autoantibodies by conven-
tional immunodiffusion assays. The 46-kD Ro autoantigen is calre-
ticulin, a calcium-binding protein that resides in the endoplasmic 
reticulum. Recombinant calreticulin has little reactivity with Ro 
autoimmune sera and its authenticity as a Ro autoantigen remains 
controversial. 
To date there has been no evidence that a targeted Ro protein or 
Ro epitope is specific for a particular type of Ro autoantibody-asso-
ciated autoimmune disorder (i.e., NLE versus SCLE versus Sjo-
gren's syndrome). In this issue (p. 963) Lee et af determine the 
frequencies at which 52- and 60-kD Ro-reactive autoantibodies are 
present in NLE sera. Their data indicate that although 52-kD Ro-
reactive autoantibodies are found frequently in NLE, 60-kD Ro-
reactive autoantibodies were found in every one of their 20 NLE 
cases. Their data suggest that the 60-kD Ro autoantibodies may play 
a larger role in NLE, but does not rule out the possibility that the 
52-kD Ro-reactive autoantibodies also contribute to the cardiac and 
skin injury in some cases of NLE. They found that the La/SS-B 
autoantibodies, which occur in parallel with Ro autoantibodies, 
occur less frequently in these patients. The U1 RNP autoantibodies, 
which have been reported previously in several cases ofNLE in the 
absence of Ro autoantibodies [3], occurred in only one of 20 NLE 
cases in this study and were accompanied by Ro autoantibodies. 
Earlier work that demonstrated greater sensitivity in Ro autoanti-
b?dy detection using nondenatured native 60-kD Ro explains the 
hlgher frequency of 60-kD Ro-reactive antibodies found in this 
study compared to an earlier NLE study (4]. Lower titers of 60-kD 
Ro-reactive autoantibodies were found in NLE patients with skin 
disease when compared to NLE patients with cardiac disease. Lee 
and colleagues propose that this finding may be a consumptive 
phenomenon from autoantibody deposition in the skin. 
These and previous data strongly suggest that the Ro autoanti-
bodies playa role in the pathogenesis ofNLE and SCLE. However, 
additional studies are needed to clarify this role and to explain why 
many infants that have acquired Ro autoantibodies transplacentally 
never develop NLE, and why some mothers that give birth to in-
fants with NLE skin disease never develop SCLE lesions. Additional 
information is required to explain why, in several reported cases, 
mothers and their infants with NLE have not had detectable Ro 
autoantibodies, and why Sjogren's syndrome patients, who usually 
have Ro autoantibodies, rarely develop SCLE. 
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